as 3201 has been researched along with Polyneuropathy, Acquired in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arezzo, J; Bradshaw, KL; Bril, V; Gordon, RJ; Junor, RW; Nash, M; Polydefkis, M; Shaibani, A | 1 |
| Bril, V; Buchanan, RA | 1 |
2 trial(s) available for as 3201 and Polyneuropathy, Acquired
| Article | Year |
|---|---|
Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy.
Topics: Aged; Diabetic Neuropathies; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Neural Conduction; Polyneuropathies; Pyrazines; Quality of Life; Spiro Compounds; Treatment Outcome | 2015 |
Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy.
Topics: Adolescent; Adult; Aged; Aldehyde Reductase; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electromyography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neural Conduction; Polyneuropathies; Probability; Pyrazines; Reference Values; Risk Assessment; Severity of Illness Index; Spiro Compounds; Sural Nerve; Treatment Outcome | 2004 |